Table 3.
Reactogenicity for patients with neuromuscular diseases.
| Dosage | B | C | BB | CC | BBB | CCC | CCB |
|---|---|---|---|---|---|---|---|
| Pain at injection site NMDs | |||||||
| NMDs | 5 (83.3) | 5 (45.5) | 3 (50.0) | 6 (54.5) | 1 (100) | 5 (55.6) | 1 (100) |
| Healthy | 93 (89.4) | 94 (54.3) | 88 (84.6) | 89 (51.5) | 11 (84.6) | 28 (46.7) | 6 (100) |
| p-value | 0.509 | 0.757 | 0.063 | 1.000 | 1.000 | 0.731 | 1.000 |
| Swelling, erythema and induration at injection site | |||||||
| NMDs | 0 (0) | 2 (18.2) | 0 (0) | 1 (9.09) | 0 (0) | 1 (11.1) | 0 (0) |
| Healthy | 10 (9.6) | 30 (17.3) | 11 (10.6) | 37 (21.4) | 4 (30.8) | 1 (1.7) | 0 (0) |
| p-value | 1.000 | 1.000 | 1.000 | 0.465 | 1.000 | 0.224 | N/A |
| Headache | |||||||
| NMDs | 0 (0) | 1 (9.09) | 3 (50.0) | 1 (9.09) | 1 (100) | 2 (22.2) | 0 (0) |
| Healthy | 22 (21.2) | 33 (19.1) | 47 (45.2) | 22 (12.7) | 9 (69.2) | 5 (8.3) | 3 (50.0) |
| p-value | 0.598 | 0.692 | 1.000 | 1.000 | 1.000 | 0.224 | 1.000 |
| Fatigue | |||||||
| NMDs | 3 (50.0) | 4 (36.4) | 4 (66.7) | 5 (45.5) | 0 (0) | 5 (55.6) | 1 (100) |
| Healthy | 50 (48.1) | 74 (42.8) | 65 (62.5) | 59 (34.1) | 9 (69.2) | 17 (28.3) | 4 (66.7) |
| p-value | 1.000 | 0.762 | 1.000 | 0.518 | 0.357 | 0.132 | 1.000 |
| Myalgia | |||||||
| NMDs | 2 (33.3) | 3 (27.3) | 1 (16.7) | 3 (27.3) | 0 (0) | 2 (22.2) | 0 (0) |
| Healthy | 25 (24.0) | 22 (12.7) | 16 (15.4) | 16 (9.25) | 8 (61.5) | 4 (6.7) | 1 (16.7) |
| p-value | 0.634 | 0.174 | 1.000 | 0.091 | 0.429 | 0.172) | 1.000 |
| Fever | |||||||
| NMDs | 0 (0) | 2 (18.2) | 1 (16.7) | 1 (9.1) | 1 (100) | 0 (0) | 0 (0) |
| Healthy | 4 (3.9) | 2 (1.16) | 16 (15.4) | 0 (0) | 5 (38.5) | 0 (0) | 1 (16.7) |
| p-value | 1.000 | 0.018 | 1.000 | 0.060 | 0.429 | 1.000 | 1.000 |
| Abdominal pain | |||||||
| NMDs | 0 (0) | 1 (9.09) | 0 (0) | 1 (9.1) | 0 (0) | 0 (0) | 0 (0) |
| Healthy | 9 (8.7) | 17 (9.8) | 9 (8.7) | 9 (5.2) | 1 (7.7) | 3 (5.0) | 1 (16.7) |
| p-value | 1.000 | 1.000 | 1.000 | 0.469 | 1.000 | 1.000 | 1.000 |
| Antipyretic use | |||||||
| NMDs | 1 (16.7) | 0 (0) | 2 (33.3) | 0 (0) | 1 (100) | 0 (0) | 0 (0) |
| Healthy | 7 (6.7) | 2 (1.2) | 25 (24.0) | 2 (1.2) | 3 (23.1) | 0 (0) | 1 (16.7) |
| p-value | 0.371 | 1.000 | 0.634 | 1.000 | 0.286 | 1.000 | 1.000 |
Healthy = healthy children and adolescents, NMDs = patients with neuromuscular diseases. B, one dose of BNT162b2; BB, two doses of BNT162b2; C, one dose of CoronaVac; CC, two doses of CoronaVac; BBB, three doses of BNT162b2; CCC, three doses of CoronaVac; CCB, two doses of CoronaVac, and one dose of BNT162b2.